Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

被引：54
|
作者：
Palomba, Maria Lia
Gordon, Leo I.
Siddiqi, Tanya
Abramson, Jeremy S.
Kamdar, Manali
Lunning, Matthew A.
Maloney, David G.
Andreadis, Charalambos
Arnason, Jon E.
Ghosh, Nilanjan
Mehta, Amitkumar
Solomon, Scott R.
Farazi, Thalia
Garcia, Jacob
Dehner, Christine
Ogasawara, Ken
Gao, Jie
Wang, Michael
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136158
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Borchmann, Peter
    Morschhauser, Franck
    Dahiya, Saurabh
    Palomba, M. Lia
    Garcia-Sancho, Alejandro Martin
    Reguera Ortega, Juan Luis
    Kuruvilla, John
    Jaeger, Ulrich
    Cartron, Guillaume
    Izutsu, Koji
    Dreyling, Martin
    Kahl, Brad
    Ghesquieres, Herve
    Ardeshna, Kirit
    Goto, Hideki
    Barbui, Anna Maria
    Abramson, Jeremy S.
    Fleury, Isabelle
    Mielke, Stephan
    Farazi, Thalia
    Fasan, Omotayo
    Lymp, James
    Vedal, Min
    Nishii, Rina
    Avilion, Ariel
    Papuga, Jessica
    Nastoupil, Loretta J.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143
  • [42] EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)
    Balasubramanian, N.
    Cummings, J.
    Lin, H.
    Raviele, A.
    Peng, L.
    Omidpanah, A.
    Espinola, R.
    Kostic, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S54 - S54
  • [43] Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT
    Bachier, Carlos R.
    Palomba, M. Lia
    Abramson, Jeremy S.
    Andreadis, Charalambos
    Sehgal, Alison
    Godwin, John
    Hildebrandt, Gerhard C.
    Siddiqi, Tanya
    Stevens, Don
    Farazi, Thalia
    Kostic, Ana
    Trede, Nikolaus S.
    Wang, Lei
    Lymp, James
    Thelen, Tennille
    Ogasawara, Ken
    Maloney, David G.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S25 - S26
  • [44] Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials
    Palomba, M. Lia
    Jun, Monika P.
    Garcia, Jacob
    Lymp, James
    McGarvey, November
    Gitlin, Matthew
    Pelletier, Corey
    Nguyen, Andy
    BLOOD, 2020, 136
  • [45] Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL
    Wang, Michael L.
    Gordon, Leo I.
    Hirayama, Alexandre V.
    Lunning, Matthew A.
    Shi, Ling
    Guo, Shien
    Kostic, Ana
    Eliason, Laurie
    Kumar, Jinender
    Palomba, Maria Lia
    BLOOD, 2023, 142
  • [46] Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
    Chanut, Mathilde
    Herbaux, Charles
    BULLETIN DU CANCER, 2023, 110 (10) : 986 - 988
  • [47] PREFERENCE-WEIGHTED HEALTH STATUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL; JCAR017) IN THE ONGOING, MULTICENTER, PHASE 1 TRANSCEND NHL 001 TRIAL
    Patrick, D.
    Matza, L.
    Kim, Y.
    Garcia, J.
    Dehner, C.
    Chung, K. C.
    VALUE IN HEALTH, 2019, 22 : S106 - S106
  • [48] Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient
    Lee, Dasom
    Goyal, Anmol
    Wang, William L.
    Ananth, Snegha
    Lau, Eric
    Binkley, Michael S.
    Bharadwaj, Sushma
    Dahiya, Saurabh
    EJHAEM, 2024, 5 (01): : 153 - 156
  • [49] Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
    Abramson, Jeremy S.
    Palomba, M. Lia
    Gordon, Leo I.
    Lunning, Matthew A.
    Wang, Michael
    Arnason, Jon E.
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison R.
    Solomon, Scott R.
    Ghosh, Nilanjan
    Kostic, Ana
    Kim, Yeonhee
    Ogasawara, Ken
    Dehner, Christine
    Siddiqi, Tanya
    BLOOD, 2021, 138
  • [50] Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience
    de la Fuente, Adolfo
    Gonzalez, Gloria
    Garcia-Carbonero, Iciar
    Garcia-Frade, Javier
    Munarriz, Javier
    Aguiar, David
    Cuevas, Beatriz
    Cuevas, Maria Victoria
    Aporta, Rafael
    Barez, Abelardo
    Callejas, Marta
    Murias, Adolfo
    Altes, Albert
    Salar, Antonio
    Sanchez-Gonzalez, Blanca
    Grande, Carlos
    Garcia-Marco, Jose A.
    Lopez, Angeles
    Moran, Marina
    Viqueira, Andrea
    Briones, Javier
    BLOOD, 2013, 122 (21)
12345